Cetera Investment Advisers Grows Stock Holdings in Edwards Lifesciences Corporation $EW

Posted by George Bondi on Aug 2nd, 2026

Cetera Investment Advisers increased its position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 13.5% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 83,953 shares of the medical research company’s stock after buying an additional 9,954 shares during the period. Cetera Investment Advisers’ holdings in Edwards Lifesciences were worth $6,723,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. MV Capital Management Inc. bought a new stake in Edwards Lifesciences during the fourth quarter valued at about $26,000. Hanson & Doremus Investment Management bought a new position in shares of Edwards Lifesciences in the first quarter worth about $25,000. Kemnay Advisory Services Inc. bought a new position in shares of Edwards Lifesciences in the fourth quarter worth about $27,000. JPL Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the third quarter worth about $25,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

EW has been the topic of a number of research analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Piper Sandler reiterated an “overweight” rating and set a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Robert W. Baird boosted their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a report on Friday, April 24th. Finally, Citigroup boosted their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $100.27.

Check Out Our Latest Stock Report on Edwards Lifesciences

Edwards Lifesciences Price Performance

EW stock opened at $86.17 on Friday. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The company has a fifty day simple moving average of $87.91 and a two-hundred day simple moving average of $83.89. The firm has a market capitalization of $49.62 billion, a P/E ratio of 49.52, a price-to-earnings-growth ratio of 2.16 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. The business had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same period last year, the company posted $0.67 EPS. The business’s revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $83.98, for a total value of $85,575.62. Following the sale, the vice president owned 33,682 shares in the company, valued at approximately $2,828,614.36. This trade represents a 2.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 44,558 shares of company stock valued at $3,770,939. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Company Profile

(Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.